100 percent of Canada is Now Screening Infants for Spinal Muscular Atrophy

We are excited to share that all babies born in Canada can now be tested for spinal muscular atrophy (SMA), a potentially fatal neuromuscular disorder. This milestone has been achieved through the leadership of Muscular Dystrophy Canada (MDC) and is the result of a three-year project working with each Canadian province and territory.

 

“This initiative holds immense value for the entire Canadian neuromuscular and rare disease community, laying the groundwork for future transformative and life-changing initiatives,” said Dr. Homira Osman, VP of Research and Public Policy, Muscular Dystrophy Canada and Co-Principal Investigator, NMD4C. “There are many progressive neuromuscular disorders where time is of the essence: early diagnosis and prompt access to treatments are critical drivers to achieving the best possible outcomes. MDC will now leverage the knowledge and findings gained from this initiative to ensure other neuromuscular disorders are included in newborn screening programs nationwide.”

Read the full press release from MDC

 

 

Highlights of the Press Release:

  • This milestone means infants diagnosed with SMA, the most fatal genetic disorder in children under two years of age, can receive life-changing treatment before symptoms even develop.
  • It marks the first neuromuscular condition to be added to screening panels across the country.
  • The addition of SMA to newborn screening panels in all provinces and territories breaks down barriers and inequities families face simply because of where they live. It also acknowledges that screening for rare genetic diseases and access to early care results in positive health outcomes and long-term cost benefits for everyone.
  • In 2020, only Ontario and the Baffin region in Nunavut screened for SMA at birth. Today, regardless of where in Canada a child is born, they will receive the same screening; and, if SMA is diagnosed, the same healthcare, treatment and opportunity to thrive.

 

For more information please contact:

Homira Osman

Vice-President Research & Public Policy

Muscular Dystrophy Canada

437-912-9037

Canada-reaches-100NBS_900px

Read next...

2025 Basic Research Summer School application image

2025 NMD4C Basic Research Summer School to be Held at York University

Save the Date! We are thrilled to announce that we will be hosting our second annual basic research summer school for neuromuscular research trainees over May 7-8, 2025 at York University in Toronto, ON.

Call for applications to join the NMD4C trainee committee

Call for Applications: Join the NMD4C’s Basic Science Trainee Committee

We are excited to share an opportunity for Canadian neuromuscular trainees to help shape the NMD4C’s basic science trainee strategy by joining the NMD4C Basic Science Trainee Committee (BSTC)!

NMD4C honored to reveive 2024 Dr David Green Award for Excellene in Service Delivery from MDC

NMD4C Honored with Dr David Green Award for Excellence in Service Delivery at MDC Awards Gala

Dr Jodi Warman-Chardon accepted the 2024 Dr David Green Excellence in Service Delivery Award on behalf of the network at the MDC Awards Gala.

2024 NMD4C Annual Meeting

NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the Annual NMD4C Meeting on September 27th in Calgary! Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date.

LEARNMD logo

NMD4C Launch Educational Platform LEARNMD

LEARNMD is an online educational platform offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide.

CNDR logo4x3

October 2024 Updates from the Canadian Neuromuscular Disease Registry

The Canadian Neuromuscular Disease Registry (CNDR) is pleased to share updates on several exciting initiatives this fall!